Finance

Lists
SGMT:NASDAQ
Sagimet Biosciences Inc
$ 8.93
+0.11%
(+0.010) 1D
$ 8.90
-0.34% (-0.030)
After hours
Closed: 10-р сарын 9, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
$ 8.84
High
$ 9.05
Low
$ 8.78
Mkt. cap
629.86 сая
Avg. vol.
1.29 сая
Volume
763.53 мян
52-wk high
$ 11.45
52-wk low
$ 4.50
EPS
-$ 1.28
Beta
3.46
Shares outstanding
70.34 сая
No. of employees
16
Open
$ 8.84
High
$ 9.05
Low
$ 8.78
Mkt. cap
629.86 сая
Avg. vol.
1.29 сая
Volume
763.53 мян
52-wk high
$ 11.45
52-wk low
$ 4.50
EPS
-$ 1.28
Beta
3.46
Shares outstanding
70.34 сая
No. of employees
16
News stories
From web sources and news partners
Stock Titan
Stock Titan
·
2 өдрийн өмнө
Inflammatory acne lesions fell 77% over 52 weeks
About Sagimet Biosciences Inc
CEO-
Employees16
Founded2006
HeadquartersSan Mateo, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current $ 8.93
$ 56.00 (+527.10%)
Average
$ 28.46 (+218.70%)
Lowest
$ 7.00 (-21.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$ 29.00
+224.7%
10/05/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$ 26.00
+191.2%
10/01/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
10/01/2026
Andrea Newkirk
Goldman Sachs
Sell
Maintained
$ 7.00
-21.6%
09/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
$ 38.00
+325.5%
10/01/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$ 56.00
+527.1%
10/01/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
$ 25.10
+181.1%
10/01/2026
Yun Zhong
Wedbush
Buy
Maintained
$ 28.00
+213.5%
10/01/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$ 27.00
+202.4%
10/01/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$ 28.00
+213.5%
09/30/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$ 31.00
+247.1%
09/27/2026
Eliana Merle
Barclays
Buy
Upgraded
$ 18.00
+101.6%
09/09/2026
Ritu Baral
TD Cowen
Buy
Maintained
$ 21.00
+135.2%
05/12/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
$ 28.00
+213.5%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$ 28.00
+213.5%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.73 сая
6.73 сая
7.00 сая
11.54 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.60 сая
4.03 сая
4.72 сая
4.28 сая
Operating expense
14.33 сая
10.76 сая
11.71 сая
15.82 сая
Total operating expenses
14.33 сая
10.76 сая
11.71 сая
15.82 сая
Operating income
-14.33 сая
-10.76 сая
-11.71 сая
-15.82 сая
Other non operating income
-
-
-
-
EBT including unusual items
-12.91 сая
-9.57 сая
-10.65 сая
-13.95 сая
EBT excluding unusual items
-12.91 сая
-9.57 сая
-10.65 сая
-13.95 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.91 сая
-9.57 сая
-10.65 сая
-13.95 сая
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.29
-0.33
-0.26
Interest and investment income
1.43 сая
1.20 сая
1.06 сая
1.86 сая
Interest expense
-
-
-
-
Net interest expenses
1.43 сая
1.20 сая
1.06 сая
1.86 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс